Compare Hut 8 Corp (HUT) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Hut 8 Corp vs Sanofi SA — how do they compare? Hut 8 Corp trades at $91 (market cap $10.94B), while Sanofi SA trades at $43.6 (market cap $104.30B). The key difference: Sanofi SA is far larger — about 9.5× Hut 8 Corp's market cap, and Sanofi SA pays a 5.55% dividend while Hut 8 Corp pays none. Which is the better fit depends on your goals.
| HUT | SNY | |
|---|---|---|
Market Cap | $10.94B | $104.30B |
Sector | Technology | Health |
52-Week High | $133.02 | $52.34 |
52-Week Low | $21.37 | $41.33 |
Enterprise Value | $18.38B | $124.19B |
Dividend Yield | — | 5.55% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HUT trades at $90.77, up 5.97% on the day, amid a broader neocloud stock rally. The technical picture is bearish with resistance at $92 and support at $87. Fundamentally, the company reported a net loss of $226.15 million in 2025 despite revenue growth, with a negative net income margin of -188.59%. Recent news highlights a significant $26.6 billion contracted backlog and $7.5 billion in project financing for AI data center development, driving investor optimism about its strategic pivot.
The outlook is mixed: strong analyst buy ratings (93.75%) and a $165.11 price target suggest upside, but persistent losses, high valuation ratios, and execution risks on new projects pose challenges. The stock's near-term direction will hinge on translating its AI infrastructure backlog into profitable growth and achieving positive cash flow.
SNY trades at $43.62, up 0.32% today, with a neutral technical signal and bullish moving averages. The company reported strong Q2 2026 earnings, beating estimates with EPS of $1.21 versus $1.10 expected, and raised its 2026 outlook. Revenue for 2025 was $46.72B with net income of $7.81B, showing improved profitability. Analyst consensus is mixed with 44% Buy, 52% Hold, and 4% Sell ratings. Recent news highlights regulatory approvals for new drugs and pipeline developments under new CEO leadership.
The outlook for SNY is cautiously optimistic, driven by Dupixent's growth and new drug approvals, but faces risks from pipeline setbacks and competition. Earnings momentum and cost discipline support upside potential, though valuation multiples like a P/E of 23.27 may limit near-term gains. Key risks include biosimilar threats post-2031 and ongoing legal challenges. Institutional activity shows increased holdings, reflecting confidence in the company's strategic direction.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Hut 8 Corp
Hut 8 is one of North America's largest digital asset miners and infrastructure providers. It operates diversified data centers supporting Bitcoin mining and high-performance computing (HPC) for AI.
Read more on HUT →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
